Sorrento Therapeutics Inc (SRNE)

[dia76ca]

Sorrento has 3 amazing portfolios. Covid. Pain. Cancer.

1. COVID. Sorrento has 18 programs in its Covid portfolio. It has the largest Covid portfolio in the world. Revenues from the Mexico EUA will accrue this year. COVISTIX, COVIDROPS, COVIMSC, ABIVERTINIB(COVID) could receive EUA's in coming months. RESPISTIX, C1 VACCINE and mRNA VACCINE have a longer timeline but broader tests and booster vaccines are clearly needed.

2. PAIN. SP-102 Pivotal phase 3 results due any day now. Lower back pain and sciatica market is $5-6 Billion. Revenue expected in 2022. RTX in cancer and arthritic pain also has enormous potential. Current non-opioid pain revenue is already nearing $100 million.

3. CANCER. ABIVERTINIB(NSCLC) approval is close in China. Both ADNAB(MAYO CLINIC) and DAR-T each have over a dozen potential targets. And CAR-T and ADC and several IO's are in phase 2.

With hundreds of millions in wise investments, rapidly increasing revenue streams and many potential worldwide marketing partnerships Sorrento is in great shape to reward its current early investors! This is a rare opportunity ... I'm glad I'm able to be part of this!